Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18).

Trial Profile

Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18).

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Oseltamivir (Primary) ; Antibacterials; Antivirals; Zanamivir
  • Indications Bacterial infections; Community-acquired pneumonia; Influenza virus infections; Respiratory tract infections
  • Focus Therapeutic Use
  • Acronyms RETOS
  • Most Recent Events

    • 11 Apr 2018 Primary endpoint (Short-term Mortality) has not been met, according to results published in the Clinical Infectious Diseases.
    • 11 Apr 2018 Primary endpoint (Re-hospitalization) has not been met, according to results published in the Clinical Infectious Diseases.
    • 11 Apr 2018 Primary endpoint (Transfer to ICU After 24 h) has not been met, according to results published in the Clinical Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top